Acadia Pharmaceuticals Inc Stock Price, News & Analysis

Acadia Pharmaceuticals (NASDAQ:ACAD) hosted its inaugural R&D Day to showcase its pipeline programs and growth strategy. The company plans to initiate seven Phase 2 or Phase 3 studies during 2025-2026, with five key readouts anticipated by 2027.

Key pipeline highlights include ACP-101 for Prader-Willi syndrome, ACP-204 for Alzheimer's and Lewy Body Dementia Psychosis, ACP-211 for major depressive disorder, ACP-711 for Essential Tremor, and ACP-271 for Tardive Dyskinesia and Huntington's Disease. The company's commercial franchises are expected to generate over $1 billion in net sales this year.

Acadia Pharmaceuticals announced inducement grants to 41 new employees under its 2024 Inducement Plan, approved by the Compensation Committee on June 6, 2025. The grants include non-qualified stock options to purchase 187,664 shares at $21.98 per share and 89,582 restricted stock units (RSUs). The stock options will vest over 4 years, with 25% vesting after one year and the remainder monthly over 36 months. RSUs will vest over 4 years, with 50% vesting at the second anniversary and the remaining in two annual installments. Acadia, known for developing the first FDA-approved drug for Parkinson's disease psychosis hallucinations and Rett syndrome treatment, continues to focus on neuroscience breakthroughs, with ongoing clinical trials in Prader-Willi syndrome and Alzheimer's disease psychosis.

The U.S. Court of Appeals for the Federal Circuit has affirmed a Delaware District Court ruling validating Acadia Pharmaceuticals' NUPLAZID (pimavanserin) '740 composition of matter patent, securing protection until 2030. This decision follows a recent favorable ruling for Acadia's formulation patent, which extends protection for the NUPLAZID 34 mg capsule formulation until 2038. The court's decision came in litigation against MSN Laboratories and builds on the precedent from Allergan USA v. MSN Laboratories case. NUPLAZID is notable as the first FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. The company is also advancing clinical-stage development programs for Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuroscience and neuro-rare diseases.

Acadia Pharmaceuticals (NASDAQ: ACAD) has announced an upcoming R&D Day event scheduled for June 25, 2025, at 8:30 AM ET in New York City. The event will focus on the company's pipeline developments in neurological and rare diseases. Participants will include Acadia's management team, R&D organization representatives, key opinion leaders (KOL), and members of the caregiver community. The event will be accessible via live webcast, with a replay available on acadia.com's investor section for approximately 3 months after the event.

Acadia Pharmaceuticals (NASDAQ: ACAD) announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference, scheduled for June 9, 2025, at 4:00 p.m. Eastern Time. The company will engage in a fireside chat that will be webcast live on Acadia.com's investor section, with the recording available for approximately one month afterward.

Acadia is a neuroscience-focused pharmaceutical company known for developing the first FDA-approved treatment for Parkinson's disease psychosis-related hallucinations and delusions, as well as the first approved drug for Rett syndrome in the US and Canada. The company's current clinical-stage pipeline includes programs targeting Prader-Willi syndrome, Alzheimer's disease psychosis, and various other neuroscience and neuro-rare diseases.

Acadia Pharmaceuticals (NASDAQ: ACAD) has appointed Allyson McMillan-Youngblood as Senior Vice President of their Rare Disease Franchise. In her new role, she will focus on maximizing the potential of DAYBUE® and preparing for future product launches in the company's rare disease portfolio. McMillan-Youngblood brings over 20 years of pharmaceutical industry experience, most recently serving as Senior Vice President and Business Unit Head of U.S. Oncology at Bristol Myers Squibb, where she led two major acquisitions in rare tumors. Her extensive background includes roles at Pfizer and BMS across various therapeutic areas including oncology, immunology, CNS, and cardiovascular disorders.

Acadia Pharmaceuticals (NASDAQ: ACAD) has granted inducement awards to 28 new employees under its 2024 Inducement Plan, as approved by the Compensation Committee. The awards include 64,252 non-qualified stock options with an exercise price of $14.81 per share and 56,277 restricted stock units (RSUs).

The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over four years, with 50% vesting after two years and the remaining 50% in two equal annual installments. Both awards are subject to continued employment.

Acadia is a neuroscience company known for developing the first FDA-approved treatment for Parkinson's disease psychosis and Rett syndrome in the US and Canada. Their pipeline includes programs for Prader-Willi syndrome and Alzheimer's disease psychosis.

Acadia Pharmaceuticals (NASDAQ: ACAD) has secured a significant legal victory in the U.S. District Court for the District of Delaware regarding its NUPLAZID® (pimavanserin) formulation patent. The court ruled in Acadia's favor against Aurobindo Pharma Limited and other ANDA filers, upholding both infringement and validity arguments for the '721 formulation patent. This ruling extends patent protection for NUPLAZID's 34 mg capsule formulation until 2038. NUPLAZID is notable as the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. The company is also advancing clinical-stage development programs focusing on Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuroscience and neuro-rare diseases.

Acadia Pharmaceuticals (NASDAQ: ACAD) reported strong Q1 2025 financial results with total revenues of $244.3 million, up 19% year-over-year. The company's two key products showed significant growth: NUPLAZID net sales reached $159.7 million (+23% YoY) and DAYBUE achieved $84.6 million (+11% YoY). DAYBUE reached a record of 954 unique patients, and the company expanded its field force by 30%. Acadia maintained its 2025 guidance with total revenues of $1.03-$1.095 billion, while increasing R&D expense guidance to $330-$350 million due to accelerated timeline for the ACP-101 Phase 3 study in Prader Willi Syndrome, now expected in early Q4 2025.

The company reported Q1 net income of $19.0 million ($0.11 per share) compared to $16.6 million ($0.10 per share) in Q4 2024. Cash position stood at $681.6 million as of March 31, 2025.